Durante los últimos 30 años, en centros de investigación de todo el mundo se ha desarrollado una terapia celular adoptiva con células efectoras inmunitarias, entre ellas una variedad de linfocitos.
Chimeric antigen receptor CAR T-cell have emerged from the lab as FDA-approved treatments for a variety of cancers. This includes some gene-modified T cells and natural (NK) cells. The future for effector cell therapy is bright, as it becomes the treatment of choice for many cancer patients. Baylor Scott & White Health will continue to play a leading role in these pioneering efforts.
Contact our patient nurse navigators in the Dallas area at 214.820.3535 or in the Temple area at 254.724.5918 for more information about CAR T and immune effector cell therapies and clinical trials.
Learn more about CAR T-cell therapy